---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-232306"
form_type: "8-K"
ticker: "VNDA"
cik: "0001347178"
company_name: "Vanda Pharmaceuticals Inc."
filed_at: "2024-10-03T23:59:59+00:00"
generated_at: "2026-05-30T21:21:30.273570+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.25
calibrated_materiality_score: 0.25
confidence: "medium"
source: SEC EDGAR
---

# Vanda amends bylaws with clarifications on special meetings, advance notice, and director nominations

## Summary
- Board approved amended bylaws effective October 2, 2024; changes include clarifying special meeting scope to agenda topics only.
- Advance notice provisions for shareholder nominations and proposals expanded with additional disclosure requirements.
- Adjournment process clarified for meetings relying on remote communication due to technical failure.
- Proxy solicitation requirements and director candidate standards spelled out more explicitly.
- Special board meetings may now be called by a majority of directors; officer definition narrowed to exclude non-officer title holders.

## SEC filing metadata
- accession: 0001193125-24-232306
- form_type: 8-K
- ticker: VNDA
- cik: 0001347178
- company_name: Vanda Pharmaceuticals Inc.
- filed_at: 2024-10-03T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.25
- calibrated_materiality_score: 0.25
- confidence: medium
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347178/000119312524232306/0001193125-24-232306-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347178/000119312524232306/d828148d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-232306
- JSON: https://secwatch.observer/filing/0001193125-24-232306.json
- Plain text: https://secwatch.observer/filing/0001193125-24-232306.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.